Warner-Lambert Sudafed sales up 7% to $43 mil.; Listerine mouthwash gains 6%.
This article was originally published in The Tan Sheet
Executive Summary
WARNER-LAMBERT SUDAFED SALES GAIN 7% IN THIRD QUARTER to $43 mil., the firm reported Oct. 22. The cold medication, one of Warner-Lambert's best performing consumer health care products in the quarter, recently was extended with Cold & Sinus gelcaps and Children's Chewable tablets. Listerine antiseptic mouthwash grew 6% to $98 mil. in the period, and Nix head lice medication increased 60% to $21 mil. Nix benefitted from an increase in the total head lice treatment category and from wider U.S. distribution
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.